Patents by Inventor Susann Taudte
Susann Taudte has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9029331Abstract: The invention relates to methods of preparing and purifying conjugates between Granulocyte Colony Stimulating Factor and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are purified using various chromatography methods.Type: GrantFiled: January 10, 2006Date of Patent: May 12, 2015Assignee: Novo Nordisk A/SInventors: Shawn DeFrees, Henrik Clausen, David A. Zopf, Caryn Bowe, Susann Taudte, Michael Felo, Walter S. Willett
-
Patent number: 8911967Abstract: The present invention provides conjugates between peptides and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention.Type: GrantFiled: May 20, 2010Date of Patent: December 16, 2014Assignee: Novo Nordisk A/SInventors: Shawn DeFrees, David A. Zopf, Susann Taudte, Walter Scott Willett, Robert J. Bayer, Matthew Kalo
-
Patent number: 8785605Abstract: The present invention relates to target binding members (e.g., antibodies) that bind a specified epitope of human IL-25. The invention also relates to target binding members (e.g., antibodies) that comprise one or more humanized antibody VL domain sequences and bind IL-25. The invention further relates to compositions comprising target binding members (e.g., antibodies) that bind IL-25, methods of producing such target binding members, and uses of such target binding members for the treatment or prevention of diseases and conditions (e.g., asthma, inflammatory bowel disease).Type: GrantFiled: March 30, 2011Date of Patent: July 22, 2014Assignee: Janssen Biotech, Inc.Inventors: Juan Carlos Almagro, Patrick Branigan, Colleen Kane, William Strohl, Susann Taudte, Mark Tornetta, John Wheeler
-
Patent number: 8519107Abstract: Interleukin-17A (IL-17A) antibody antagonists, polynucleotides encoding IL-17A antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.Type: GrantFiled: October 29, 2010Date of Patent: August 27, 2013Assignee: Janssen Biotech, Inc.Inventors: Juan Carlos Almagro, Daniela Della Ducata, Merle Elloso, Jinquan Luo, Thomas Malia, Michael Naso, Galina Obmolova, Robert Rauchenberger, Mark Rutz, Raymond Sweet, Susann Taudte, Bingyuan Wu, Sheng-Jiun Wu
-
Publication number: 20110318353Abstract: The present invention relates to target binding members (e.g., antibodies) that bind a specified epitope of human IL-25. The invention also relates to target binding members (e.g., antibodies) that comprise one or more humanized antibody VL domain sequences and bind IL-25. The invention further relates to compositions comprising target binding members (e.g., antibodies) that bind IL-25, methods of producing such target binding members, and uses of such target binding members for the treatment or prevention of diseases and conditions (e.g., asthma, inflammatory bowel disease).Type: ApplicationFiled: March 30, 2011Publication date: December 29, 2011Inventors: Juan Carlos Almagro, Patrick Branigan, Colleen Kane, William Strohl, Susann Taudte, Mark Tornetta, John Wheeler
-
Publication number: 20110236390Abstract: Interleukin-17A (IL-17A) antibody antagonists, polynucleotides encoding IL-17A antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.Type: ApplicationFiled: October 29, 2010Publication date: September 29, 2011Inventors: Juan Carlos Almagro, Daniela Della Ducata, Merle Elloso, Jinquan Luo, Thomas Malia, Michael Naso, Galina Obmolova, Robert Rauchenberger, Mark Rutz, Raymond Sweet, Susann Taudte, Bingyuan Wu, Sheng-Jiun Wu
-
Publication number: 20100330645Abstract: The present invention provides conjugates between peptides and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention.Type: ApplicationFiled: May 20, 2010Publication date: December 30, 2010Applicant: NOVO NORDISK A/SInventors: Shawn DeFrees, David A. Zopf, Susann Taudte, Walter Scott Willett, Robert J. Bayer, Matthew Kalo
-
Publication number: 20100113743Abstract: The present invention provides conjugates between Factor VII or Factor VIIa peptides and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention.Type: ApplicationFiled: October 23, 2009Publication date: May 6, 2010Applicant: Novo Nordisk A/SInventors: Shawn DeFrees, David A. Zopf, Susann Taudte, W. Scott Willett, Matthew Kalo, Robert J. Bayer
-
Publication number: 20090305967Abstract: The present invention provides conjugates between Factor VII or Factor VIIa peptides and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention.Type: ApplicationFiled: August 21, 2006Publication date: December 10, 2009Applicant: Novo Nordisk A/SInventors: Shawn DeFrees, David A. Zopf, Susann Taudte, Walter S. Willett, Mattew Kalo, Robert J. Bayer
-
Publication number: 20090203579Abstract: The present invention provides conjugates between Granulocyte Colony Stimulating Factor and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention.Type: ApplicationFiled: January 10, 2006Publication date: August 13, 2009Inventors: Shawn Defrees, Henrik Clausen, David A. Zopf, Caryn Bowe, Susann Taudte, Michael Felo, Walter S. Willett
-
Publication number: 20070105755Abstract: The present invention provides conjugates between peptides and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention.Type: ApplicationFiled: October 13, 2006Publication date: May 10, 2007Applicant: Neose Technologies, Inc.Inventors: Shawn DeFrees, David Zopf, Susann Taudte, Walter Willett, Robert Bayer, Matthew Kalo